We are happy to announce that the first two patients have been successfully randomized in the Phase 2 portion of the clinical trial evaluating golexanolone for the treatment of cognitive symptoms in Primary Biliary Cholangitis (PBC).
This randomized, double-blind, placebo-controlled study aims to assess the efficacy of golexanolone in improving cognitive function, fatigue, and daytime sleepiness in PBC patients. With over 30 clinical research centers across Europe participating, this study has the potential to bring a much-needed treatment option for the debilitating cognitive symptoms associated with PBC.
We are proud to be part of this groundbreaking research effort and look forward to supporting Umecrine Cognition AB in achieving further milestones as the study progresses.
You can read the full press release HERE on at Umecrine’s website.
